Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2000-09-01
2002-09-17
Gitomer, Ralph (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S033000, C514S248000, C424S485000, C424S486000
Reexamination Certificate
active
06451837
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to a method of treatment to achieve neuroprotection of cells in the central nervous system from death and for stimulating nerve cell survival in subjects with neurodegenerative disorders.
BACKGROUND OF THE INVENTION
Pathological conditions resulting from the accelerated or ongoing death of nerve cells in the central nervous system are prevalent in today's society and include acute or chronic neurodegenerative disorders. An example of a chronic neurodegenerative disorder is Alzheimer's disease. Other examples of neurodegenerative disorders include Parkinson's disease; Huntington's disease; AIDS Dementia; Wernicke-Korsakoff's related dementia (alcohol induced dementia); age related dementia; age associated memory impairment; brain cell loss due to head trauma, stroke, hypoglycemia, ischemia, anoxia, hypoxia, cerebral edema, arteriosclerosis, hematoma or epilepsy; spinal cord cell loss due to any of the conditions listed under brain cell loss; and peripheral neuropathy. Chronic and acute neurodegenerative diseases and acute nerve cell injury, as well as associated mortality and morbidity, have been largely untreatable with previous methods. Patient disability resulting from these conditions can cause a significant reduction in quality of life. In addition, these conditions impose a high cost to the patient and to society for long term care. Accordingly, effective therapeutic approaches directed to the prevention or reduction of nerve cell death or nerve cell damage associated with neurodegenerative diseases and acute nerve cell injury are needed. Specifically, an efficacious method for treating conditions in the brain resulting from neuron loss is needed that is relatively non-toxic, suitable for use in both females and males, and which can readily access the brain across the blood-brain barrier. The terms “nerve cells” and “neurons” are used interchangeably herein to refer to cells in the central nervous system, including the brain.
1. The Mechanism of Neuron Damage
The amino acids glutamate and aspartate are known to function as excitatory neurotransmitters in the mammalian central nervous system. These amino acids activate a large series of excitatory neurotransmitter receptors known as “glutamate receptors”. These glutamate receptors, along with the various neurotransmitters which activate them, make up the “glutamatergic system”, the dominant excitatory nerve impulse transmission system of the mammalian central nervous system. A detailed explanation of the functioning of the glutamatergic system can be found in Olney, et al., U.S. Pat. No. 5,902,815.
Over the last few years, it has come to be recognized that overstimulation of excitatory neurotransmitter receptors can have serious pathological consequences for nerve cells. The overstimulation of cultured nerve cells in vitro by glutamate, for example, can lead to nerve cell death. Nerve cell death caused by such overstimulation is referred to as “excitotoxicity.” Excitotoxicity is thought to be important in the pathogenesis of several neurodegenerative disorders, including stroke and ischemic injury. Excitotoxicity has been studied in vivo and in vitro, including in organotypic hippocampal explant preparations. Excitotoxicity is caused by Ca
2+
overload resulting from its influx through highly Ca
2+
-permeable glutamate receptors sensitive to N-methyl-D-aspartate (“NMDA”) receptors and the resulting activation of intracellular kinases. One of the first events associated with excitotoxicity and nerve cell death is activation of protein kinase C (“PKC”). It has been shown that inhibition or reduction of PKC formation protects against nerve cell death following ischemia.
PKC refers to a family of more than ten Ca
2+
/phospholipid-dependent and independent threonine-serine kinase isozymes which regulate a multitude of mechanisms including cell differentiation and response to injury. PKC is abundant in neurons. It has been established that ischemia affects PKC activity and distribution. Ischemic nerve cell death has been associated with induction of PKC-delta isozyme. This effect can be blocked by NMDA inhibitors. Increased PKC-gamma immunoreactivity following incomplete ischemia has been found in the hippocampus. It has been shown that NMDA receptor stimulation can trigger PKC-gamma and beta isozyme activation. Protection of cultures by the NMDA antagonist MK-801 (dizocilpine maleate) has been associated with increases in PKC gamma, lambda, iota and micron isozymes, and PKC epsilon. PKC alpha, beta
1
, beta
2
remained unchanged suggesting that PKC isozymes can play a significant role in regulating cell death. These data are consistent with the view that inhibition of PKC can confer neuroprotection.
2. The MAPK Cascade
Several PKC isozymes (for example, PKC-delta and epsilon) activate the mitogen-activated protein kinase (MAPK) cascade. The MAPK family consists of key regulatory proteins that are known to regulate cellular responses to both proliferative and stress signals. MAPK is abundantly expressed in nerve cells and may be necessary for cellular commitment to apoptosis. Apoptosis, also know as “programmed cell death”, is a mechanism of nerve cell death initiated by activation of intracellular enzymes known as caspases. When a cell is undergoing the apoptotic process, its membrane disintegrates which exposes the inside of the membrane's lipid bilayer. This process is sometimes referred to as the “phosphatidylserine flip-flop.”
It is believed that nerve cells will enter apoptosis if they are stimulated with a mitogenic agent, forcing them to divide. Nerve cells normally cannot divide, and if forced to divide, they instead enter the apoptosis program and die. Nerve cells may enter the division cycle when the MAPK cascade is activated. Accordingly, blocking the MAPK cascade can protect nerve cells from death.
MAPKs consist of several enzymes, including a subfamily of extracellular signal-activated kinases (ERK1 and ERK2) and stress-activated MAPKs. There are three distinct groups of MAPKs in mammalian cells: a) extracellular signal-regulated kinases (ERKs), b) c-Jun N-terminal kinases (JNKs) and c) stress activated protein kinases (SAPKs). As used herein, the term “MAPK cascade” refers to those protein kinases or protein kinase cascades located within nerve cells that are inhibited by 2-(2′amino-3′ methoxphenyll)-oxanaphthalen-4-one(referred to herein” PD098059), apigenin, or other similar bioflavonoids and which, upon activation, activate various transcription factors. Other as yet uncharacterized protein kinases which are similarly inhibited by PD098059 or apigenin and which are located within nerve cells, and which, upon activation, activate various transcription factors, are also within the scope of the term “MAPK cascade”.
An example of the MAPK cascade can be described as follows. PKC activation or other factors (e.g. increases in free intracellular Ca
2+
) activates small proteins called Ras/Raf-1, which in turn activate MAPK/ERK kinases referred to as MEKs. The MEKS in turn activate ERKs. The ERKS translocate to the cell nucleus where they activate transcription factors and thereby regulate cell proliferation. The inhibition of these protein kinases produces neuroprotective and neuron-treating effects as does the inhibition of the MAPK cascade. Examples of such kinases are mitogen-activated protein kinase 1 and 2, their homologues and isoforms, extracellular signal-regulated kinases (ERKs) their homologues and isoforms (ERK1, ERK2, ERK3, ERK4), and a group of kinases known as MAP/ERK kinases 1 and 2 or MEK1/2.
Exposure of cells to stress activates protein kinases by a variety of mechanisms. For example, ischemia, NMDA and amyloid peptides activate MAPK. Studies of functional roles of MAPKs in nerve tissue suggest that MAPK could be an important regulator of nerve cell death and plasticity. Thus, MAPK activation is required for hippocampal long-term potentiation (LTP). Okadaic acid, an inhibitor of protein
Cummings & Lockwood LLC
Gitomer Ralph
Khare Devesh
LandOfFree
Neuroprotective effects of mitogen-activated protein kinase... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroprotective effects of mitogen-activated protein kinase..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroprotective effects of mitogen-activated protein kinase... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2832650